Sunil Badve
@Badves
Followers
1K
Following
7K
Media
221
Statuses
3K
Nephrologist, Conjoint Professor of Medicine @UNSWMedicine @georgeinstitute. 'Science is a way of thinking much more than it is a body of knowledge.' Carl Sagan
Joined November 2012
Excited to share our latest study showing kidney, CV and survival benefits of GLP-1 receptor agonists just published in @TheLancetEndo Time-limited free access https://t.co/skhqzkBvVg 1/
1
8
25
@SabeloShezi_ Cystatin C is normal. He does not have CKD Cr in the blood reflects production (muscle mass dependent) & GFR. Think of cystatin C as a muscle mass ignorant Cr level. Most creatine OTC formulations do not increase Cr contrary to popular belief, Kid Int (2019) 96, 527–528
3
6
36
KDIGO is pleased to share the newly published report from its Controversies Conference on Preventing CKD and Maintaining Kidney Health, now available in press in @Kidney_Int. 📄Download the report: https://t.co/hF9ZPtVIZv 📘 Read the report in KI: https://t.co/m4cGoYjj5T
1
141
296
IMJ June 2025 #FreeAccess Editorial: Smokers and kidney transplantation assessment: a question of risk or equity? https://t.co/u7345Eo43y
@TheRACP @WileyHealth @Badves
0
3
3
IMJ June 2025 #OpenAccess Editor's choice (Original Article): Smoking and kidney transplantation wait listing https://t.co/MwBW1Imqvf
@TheRACP @WileyHealth @Badves
0
3
4
Save the date for Kidney Supportive Care Masterclass 2025 and Serious Illness Conversations Workshop. Open to nephrologists, nephrology trainees and nurse practitioners. Separate registrations for the Masterclass ( https://t.co/zn3wPuHwRw) and the Workshop (email in the image).
0
0
4
In SOUL, 2596/9650 (26.9%) participants were receiving SGLT2i at baseline (largest CVOT of combined GLP-1/SGLT2 to date) The effect of oral semaglutide on cardiovascular outcomes was consistent, regardless of SGLT2i use #ACC25
https://t.co/4KDVIV2wOf
1
24
51
Cardiovascular, Kidney & Mortality Outcomes With Injectable & Oral GLP1-RA in T2 Diabetes An updated meta-analysis of >70,000 patients after the SOUL trial by @matthewmylee et al. ⬇️ 14% MACE ⬇️ 14% heart failure ⬇️ 17% CKD ⬇️ 12% all-cause mortality https://t.co/6yGDiCjDl0
1
32
64
Evidence is thin that hypertension causes chronic kidney disease.
academic.oup.com
In 1936, Kimmelstiel and Wilson wrote, “owing to the reciprocal relationship of hypertension and kidney disease, the later states of both conditions often
9
45
123
A randomized controlled trial evaluated the efficacy and safety of #apixaban for prevention of recurrent thrombosis after #thrombectomy of #hemodialysis #vascularaccess
https://t.co/eyocsHisdX
0
16
64
@LRSorce @SebastianPalmqv @NiklasMattsson4 @criticcaredoc @TobyMMaher @AlexSpyropoul Most Viewed JAMA 2024: Medications for Obesity 🔗 https://t.co/AaQMJOBswF
@DrRobertKushner
1
7
19
#SimPub #CircESC2024In type 2 diabetes, GLP-1RA reduce the risk of CV & renal outcomes, independent of SGLT2i @georgeinstitute @brendonneuen
https://t.co/oE9diO3Kka
0
9
16
📢 #GLP1 receptor agonists improve both kidney- and heart-related clinical outcomes for individuals with: ▶️ #type2diabetes ▶️ #chronickidneydisease ▶️ #overweight and #obesity
@Nephronline @CardiologyToday @TheLancetEndo @Badves @georgeinstitute
https://t.co/E44PNbUWlP
healio.com
GLP-1 receptor agonists improved clinical outcomes related to kidney and heart health while lowering mortality rates for individuals with diabetes, chronic kidney disease or preexisting cardiovascu...
0
3
3
Clear reductions in all outcomes with GLP-1RA: Kidney failure ✅ Major CV events ✅ Heart failure ✅ CV death ✅ All-cause death ✅ Updated systematic review/meta-analysis of 11 trials ~85,000 participants, with & without diabetes Now in @TheLancetEndo
https://t.co/o60CmZeZgm
2
41
98
New—Effects of #GLP-1 receptor agonists on #kidney and #cardiovascular disease outcomes: a meta-analysis of randomised controlled trials https://t.co/aVZ4Kcd3Bb
#T2D #CVD
1
11
35
Popular diabetes drugs like Ozempic can reduce the risk of kidney failure and death due to kidney or cardiovascular causes in people with and without diabetes, new research from @Badves and @VladoPerkovic shows. @georgeinstitute
https://t.co/ClEtvRqo1c
unsw.edu.au
Diabetes drugs have been found to reduce the risk of kidney failure and protect cardiovascular health in people with and without diabetes.
0
1
3
Take home message: as @KatherineTuttl8 says GLP-1 receptor agonists save kidneys and hearts, and lives. #glp1inate 5/5
1
1
3
GLP-1 receptor agonists are the first and only class of medications with proven benefits for composite kidney and cardiovascular outcomes, all individual components of composite kidney and cardiovascular outcomes, all-cause death and hospitalisation for heart failure. 4/
1
0
3
Our study shows significant reduction in the risk of kidney failure with GLP-1 receptor agonists for the first time, suggesting that the kidney benefits of GLP-1 receptor agonists are real and not due to reduced muscle mass affecting creatinine-based eGFR measurements. 3/
1
0
3
Coauthors: @matthewmylee @P_Rossing @TheMahaf @KatherineTuttl8 @RpratleyMD @VladoPerkovic Anika Bilal, Naveed Sattar, Hertzel Gerstein, Christian Ruff, John J V McMurray, George Bakris, Johannes F E Mann, Helen M Colhoun @georgeinstitute @UNSWMedicine 2/
1
1
3